2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide | 57966-95-7

• 物质功能分类: 化学农药原药 - 杀菌剂 - 其他杀菌剂
• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide
• 英文别名: 1-(2-cyano-2-methoxyiminoacetyl)-3-ethylurea；Cymoxanil；curzate；1-{2-cyano-2-[(E)-methoxyimino]-acetyl}-3-ethyl-urea；1-(2-cyano-2-methoxyiminoacetyl)-3-ethyl urea；(1E)-2-(ethylcarbamoylamino)-N-methoxy-2-oxoethanimidoyl cyanide
• CAS: 57966-95-7
• 化学式: C₇H₁₀N₄O₃
• 分子量: 198.181
• InChiKey: XERJKGMBORTKEO-VZUCSPMQSA-N

物化性质

• 熔点：
  160-161°
• 沸点：
  335.48°C (rough estimate)
• 密度：
  1.3841 (rough estimate)
• 闪点：
  100 °C
• 溶解度：
  二甲基亚砜：100 mg/mL（504.59 mM）
• LogP：
  0.590
• 颜色/状态：
  Colorless crystals
• 气味：
  Odorless
• 蒸汽压力：
  1.13X10-6 mm Hg at 20 °C
• 分解：
  When heated to decomposition it emits toxic vapors of /nitrogen oxides/.
• 解离常数：
  pKa = 9.7 (decomposes)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  5

ADMET

代谢

在粪便中完整地检测到了（14）C-cymoxanil（小于1%）和IN W3595，但大部分放射性为（14）C-glycine（约9-13%）。根据数据，代谢途径涉及将cymoxanil水解为IN W3595，然后将其降解为glycine，glycine进而被并入天然成分或进一步代谢。

... In feces intact (14)C-cymoxanil (< 1%) and IN W3595 was detected, but the majority of radioactivity was (14)C-glycine (about 9 - 13%). Based on the data, the metabolic pathway involves hydrolysis of cymoxanil to IN W3595, which is then degraded to glycine, which in turn is incorporated into natural constituents or further metabolized.

来源:Hazardous Substances Data Bank (HSDB)

代谢

IN-U3204（1-乙基-5,6-二-2,4(1H,3H)吡啶二酮）在用120毫克/千克DPX-3217处理的动物的两性混合0-48小时尿样中被检测到，以及在正在进行的一项低剂量胆管瘘研究中，用2.5毫克/千克处理的动物的两性混合0-24小时样本中被检测到。后一组被包括在内是为了确保IN-U3204的存在不是储存的人为产物；尽管在明显低水平上，IN-U3204在这两组中都被检测到。

... IN-U3204 (1-ethyl-5,6-di-2,4(1H,3H) pyridinedione) was detected in pooled 0-48 hr urine samples, both sexes, from animals treated with 120 mg/kg DPX-3217 and in pooled 0-24 hr samples, both sexes, from animals treated with 2.5 mg/kg in an ongoing low dose biliary fistula study. The latter group was included to ensure that the presence of IN-U3204 was not an artifact of storage; IN-U3204 was detected in both groups, though at apparently low levels.

来源:Hazardous Substances Data Bank (HSDB)

代谢

/2-(14)C-DPX-T3217/ 以玉米油形式给大鼠单次给药：剂量组分别为2.5 & 120 mg/kg，0.5 & 2 mL/只动物（大约10 & ~20 uCi/只动物，分别为D组和E组），以及一个多次给药组：每天给药2.5 mg/kg，连续14天，然后给予标记剂量2.5 mg/kg（F组）。在5性别/剂量方案中，通过HPLC和TLC检测到的排泄物中的主要代谢物是IN-W3595（2-氰基-2-甲氧基亚氨基乙酸）和极性成分（甘氨酸和其他氨基酸结合物）；在D组雄性大鼠中，24小时内：58%的给药剂量（AD）出现在尿液中（8.6%为IN-W3595，46.5%为极性成分），21.9%出现在粪便中（14%可提取，<1% IN-W3595，13.1%极性成分）。在D组雌性大鼠中，64.2%的AD出现在尿液中（16.1% IN-W3595，45.2%极性成分），16.3%出现在粪便中（10.1%可提取，<1% IN-W3595，8.7%极性成分）。在E组雄性大鼠中，70.3%的AD出现在尿液中（26.3% IN-W3595，40.3%极性成分），16.1%出现在粪便中（11.3%可提取，<1% IN-W3595，8.6%极性成分）。在E组雌性大鼠中，73%的AD出现在尿液中（33% IN-W3595，36.7%极性成分），17.1%出现在粪便中（11.5%可提取，<1% IN-W3595，8.5%极性成分）。在F组雄性大鼠中，66.2%的AD出现在尿液中（6.5% IN-W3595，55%极性成分），14.5%出现在粪便中（9%可提取，<1% IN-W3595，8.9%极性成分）。在F组雌性大鼠中，63.1%的AD出现在尿液中（11.1% IN-W3595，46.6%极性成分），19.4%出现在粪便中（12.3%可提取，<1% IN-W3595，12.2%极性成分）。/IN-W3595代谢物/

/2-(14)C-DPX-T3217/ was administered /to rats/ in corn oil to/ single dose groups: 2.5 & 120 mg/kg, 0.5 & 2 mL/animal (~10 & ~20 uCi/animal, groups D & E, respectively) and a multiple dose group: daily administration at 2.5 mg/kg for 14 days followed by labeled dose at 2.5 mg/kg (group F). /In a/ 5/sex/dose regimen, the primary metabolites detected by HPLC and TLC in excreta were IN-W3595 (2-cyano-2-methoxyimino acetic acid) and polar components (glycine and other amino acid conjugates); In group D males, 24 hr: 58% of /administered dose (AD)/ in urine (8.6% as IN-W3595, 46.5% as polars), 21.9% in feces (14% extractable, <1% IN-W3595, 13.1% polars). In /group D/ females, 64.2% of AD /appeared/ in urine (16.1% IN-W3595, 45.2% polars), 16.3% in feces (10.1% extractable, <1% IN-W3595, 8.7% polars). In group E males, 70.3% of AD /appeared/ in urine (26.3% IN-W3595, 40.3% polars), 16.1% in feces (11.3% extractable, <1% IN-W3595, 8.6% polars). /In group E/ females, 73% of AD in urine (33% IN-W3595, 36.7% polars), 17.1% in feces (11.5% extractable, <1% IN-W3595, 8.5% polars). In group F males, 66.2% of AD /appeared/ in urine (6.5% IN-W3595, 55% polars), 14.5% in feces (9% extractable, <1% IN-W3595, 8.9% polars). In group F females, 63.1% of AD /appeared/ in urine (11.1% IN-W3595, 46.6% polars), 19.4% in feces (12.3% extractable, <1% IN-W3595, 12.2% polars). /IN-W3595 metabolite/

来源:Hazardous Substances Data Bank (HSDB)

代谢

有机腈通过肝脏中的细胞色素P450酶的作用转化为氰化物离子。氰化物迅速被吸收并在全身分布。氰化物主要通过罗丹酶或3-巯基丙酸硫转移酶代谢为硫氰酸盐。氰化物代谢物通过尿液排出。

Organic nitriles are converted into cyanide ions through the action of cytochrome P450 enzymes in the liver. Cyanide is rapidly absorbed and distributed throughout the body. Cyanide is mainly metabolized into thiocyanate by either rhodanese or 3-mercaptopyruvate sulfur transferase. Cyanide metabolites are excreted in the urine. (L96)

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 毒性总结

有机腈在体内和体外都会分解成氰化物离子。因此，有机腈的主要毒性机制是它们产生有毒的氰化物离子或氢氰酸。氰化物是电子传递链第四个复合体（存在于真核细胞线粒体膜中）中的细胞色素c氧化酶的抑制剂。它与这种酶中的三价铁原子形成复合物。氰化物与这种细胞色素的结合阻止了电子从细胞色素c氧化酶传递到氧气。结果，电子传递链被中断，细胞无法再通过有氧呼吸产生ATP能量。主要依赖有氧呼吸的组织，如中枢神经系统和心脏，受到特别影响。氰化物也通过绑定过氧化氢酶、谷胱甘肽过氧化物酶、变性血红蛋白、羟钴胺素、磷酸酶、酪氨酸酶、抗坏血酸氧化酶、黄嘌呤氧化酶、琥珀酸脱氢酶和Cu/Zn超氧化物歧化酶产生一些毒性效应。氰化物与变性血红蛋白中的三价铁离子结合形成无活性的氰化变性血红蛋白。

Organic nitriles decompose into cyanide ions both in vivo and in vitro. Consequently the primary mechanism of toxicity for organic nitriles is their production of toxic cyanide ions or hydrogen cyanide. Cyanide is an inhibitor of cytochrome c oxidase in the fourth complex of the electron transport chain (found in the membrane of the mitochondria of eukaryotic cells). It complexes with the ferric iron atom in this enzyme. The binding of cyanide to this cytochrome prevents transport of electrons from cytochrome c oxidase to oxygen. As a result, the electron transport chain is disrupted and the cell can no longer aerobically produce ATP for energy. Tissues that mainly depend on aerobic respiration, such as the central nervous system and the heart, are particularly affected. Cyanide is also known produce some of its toxic effects by binding to catalase, glutathione peroxidase, methemoglobin, hydroxocobalamin, phosphatase, tyrosinase, ascorbic acid oxidase, xanthine oxidase, succinic dehydrogenase, and Cu/Zn superoxide dismutase. Cyanide binds to the ferric ion of methemoglobin to form inactive cyanmethemoglobin. (L97)

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 致癌性证据

癌症分类：不太可能对人类致癌

Cancer Classification: Not Likely to be Carcinogenic to Humans

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 致癌物分类

对人类无致癌性（未列入国际癌症研究机构IARC清单）。

No indication of carcinogenicity to humans (not listed by IARC).

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 副作用

皮肤致敏剂 - 一种可以诱导皮肤产生过敏反应的制剂。

Skin Sensitizer - An agent that can induce an allergic reaction in the skin.

来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases

毒理性

• 毒性数据

LCLo（大鼠）= 4,980 毫克/立方米/4小时

LCLo (rat) = 4,980 mg/m3/4h

来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases

吸收、分配和排泄

赛默昔尼尔（Cymoxanil）能够迅速被吸收，给药后4小时内血液和血浆中达到最大浓度。在48小时内，观察到尿液和粪便中快速且几乎完全排除了所给予的放射性剂量。排泄主要通过尿液（64 - 75%），粪便（16 - 24%）和呼出气体（< 5%）进行。在性别、剂量水平或单次或多次给药之间，残留物轮廓或消除率没有显著差异。没有检测到生物积累的证据。DPX-T3217被广泛代谢，尿液中仅检测到微量的所给予的(14)C-赛默昔尼尔。...

Cymoxanil is rapidly absorbed and maximum concentrations in the blood and plasma is reached within 4 hours after dosing. Rapid and almost complete elimination of the administered radioactive dose was observed in urine and feces within 48 hours. Excretion is primarily by urine (64 - 75%), fecal (16 - 24%) and expired air (< 5%) of the administered dose. There is no significant difference in residue profiles or elimination rates between sexes, dose levels, or single or multiple dosing. No evidence of bioaccumulation was detected. DPX-T3217 is metabolized extensively and only trace level of the administered (14)C-cymoxanil was detected in the urine and feces. ...

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

每性别五只带有胆管插管的SD大鼠口服给予了2.5毫克/千克的(14)C-Cymoxanil（放射性纯度=98%; 14.09 uCi/mg），以玉米油悬浮液形式。在48小时的时间内收集尿液、粪便和胆汁，之后处死动物，并收集全血、肝脏、肾脏和剩余尸体以测量放射性标记。...在48小时内，超过85%的测试化合物通过尿液（大约65%）、粪便（大约14%）和胆汁（大约7%）排出，大部分在最初的24小时内排出；极性氨基酸结合物是尿液中（大约45-50%）和胆汁中（大约4-6%）发现的主要代谢物类别；代谢物A（未知）和IN-W3595/(2-氰基-2-甲氧亚氨基乙酸)/在尿液中的浓度较低（<10%）。IN-W3595在雌性大鼠尿液中的浓度（7.7%）高于雄性（2.8%）；代谢物A在胆汁中未发现。

Five SD rats/sex with cannulated bile ducts were dosed orally with 2.5 mg/kg of (14)C-Cymoxanil (radiochemical purity = 98%; 14.09 uCi/mg) as a corn oil suspension. Urine, feces, and bile were collected over a 48 h period, after which the animals were terminated and whole blood, liver, kidneys, and residual carcass were collected for measurement of radiolabel. ...More than 85% of the test compound was eliminated in urine ( approximately 65%), feces (approximately 14%), and bile (approximately 7%) within 48 hr in both sexes, with most elimination occurring with the first 24 hr; polar amino acid conjugates comprised the major class of metabolites found in both urine (approximately 45-50%) and bile (approximately 4-6%); Metabolite A (unknown) and IN-W3595 /(2-cyano-2-methoxyimino acetic acid)/ were found at much lower concentrations (< 10%) in urine. IN-W3595 was found at higher concentrations in the urine of females (7.7%) as compared to males (2.8%); Metabolite A was not found in bile.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

为了研究2-(14)C-DPX-T3217在大鼠体内的吸收、分布、代谢和排泄，以玉米油为溶剂，分别以2.5毫克/千克和120毫克/千克的剂量给药，每只动物的给药体积分别为0.5毫升和2毫升。放射性剂量大约为每只动物10微居里和20微居里。高剂量是根据预期的轻微毒性来设定的。通过单次灌胃给药：每剂量性别3只动物用于血液药代动力学研究，5只用于排泄/分布研究，8只用于组织分布研究；多次给药（在2.5毫克/千克的冷剂量下连续给药14天，然后给予标记剂量）：每性别5只动物；血液/血浆和组织残留轮廓在各组之间没有显著差异。最大血液浓度在4小时内达到；高剂量（两个性别）和多次低剂量（仅限雄性）的相对粪便排泄量可能略有减少。在比较性别、剂量或单次与多次给药方案时，排泄时间或途径没有显著差异。包括所有剂量组，24小时内57-65%的给药剂量（AD）在尿液中回收，5-17%在粪便中；96小时内63-75%在尿液中，16-24%在粪便中；在96小时时，组织中剩余的AD小于1%（在肾脏、肝脏和皮肤中找到的最高水平）。

/To study the absorption, distribution, metabolism, and excretion of 2-(14)C-DPX-T3217 in rats, doses of/ 2.5 & 120 mg/kg in corn oil /at/ 0.5 & 2 mL/animal, /were administered. Radioactivity amounted to/ ~10 & ~20 uCi/animal, respectively. /High dose/ set by expectation of slight toxicity. /With/ single gavage administration: 3/sex/dose - blood pharmacokinetics, 5/sex/dose - elimination/distribution, 8/sex/dose - tissue distribution; multiple administration (cold dosing at 2.5 mg/kg for 14 days followed by labeled dose): 5/sex; no significant differences between groups in blood/plasma and tissue residue profiles. Max. blood concentrations were attained by 4 hr; with the possible exception of a somewhat decreased relative fecal excretion at the high dose (both sexes) and at the multiple low dose (males only). No significant differences in excretion time or route were seen when comparing sexes, doses, or single vs. multiple dosing regimens. Including all dose groups, 57-65% of the administered dose (AD) recovered in urine & 5-17% in feces by 24 hr, 63-75% in urine & 16-24% in feces by 96 hr; at 96 hr <1% of AD remained in tissues (highest levels found in kidney, liver, & skin).

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

(14)C-Cymoxanil施用到番茄植株的根系或叶面上，通过放射自显影、燃烧和薄层色谱分析水或甲醇提取物来跟踪其吸收、传输和降解情况。Cymoxanil在1小时内被根系吸收，并在16小时内传输到子叶、茎和叶片。该化合物在16-44小时内主要降解为甘氨酸，在根系和所有地上部分。当将(14)C-cymoxanil施用到五叶植物的叶2表面时，与单独施用(14)C-cymoxanil的植物相比，使用甲霜灵和(14)C-cymoxanil混合物处理的植物中(14)C-cymoxanil的吸收、传输和降解（主要转化为甘氨酸）有所增强。根系施用的数据确认了cymoxanil在番茄植株中是一种具有短暂持效的系统化合物。叶面施用的数据表明，cymoxanil、甲霜灵和代森锰锌之间在控制由霜霉目引起的植物病害方面已知的协同作用，并不是由于在存在其他杀菌剂时cymoxanil降解延迟；协同作用的机制尚未阐明。

(14)C-Cymoxanil was applied to either the root system or to the foliage of tomato plants and its uptake, translocation and degradation was followed using autoradiography, combustion and thin-layer chromatographic analyses of water or methanolic extracts. Cymoxanil was taken up by the root system within 1 hr and translocated to cotyledons, stem and leaves within 16 hr. The compound was degraded, mostly to glycine, within 16-44 h, in the root and all parts of the shoot. When applied to the surface of leaf 2 of five-leaf plants, enhanced uptake, translocation and degradation (mainly to glycine) of (14)C-cymoxanil was observed in plants treated with a mixture of oxadixyl and (14)C-cymoxanil, compared with plants treated with (14)C-cymoxanil alone. Root application data confirm that cymoxanil is a systemic compound with a short persistence in tomato plants. Foliage application data suggest that the well-documented synergistic interaction between cymoxanil, oxadixyl and mancozeb in controlling plant diseases caused by Peronosporales does not result from a delayed degradation of cymoxanil in the presence of the other fungicides; the mechanism of synergism has not yet been elucidated.

来源:Hazardous Substances Data Bank (HSDB)

安全信息

• 危险等级：
  9
• 危险品标志：
  Xn
• 安全说明：
  S36/37,S60,S61
• 危险类别码：
  R22,R50/53,R43
• WGK Germany：
  3
• 海关编码：
  2926909038
• 危险品运输编号：
  UN 3077
• RTECS号：
  AB5957000

制备方法与用途

毒性

原药对大鼠急性经口LD₅₀为1196毫克/公斤，豚鼠为1096毫克/公斤。兔急性经皮LD₅₀大于3000毫克/公斤。该物质对眼睛有轻度刺激，但无皮肤刺激作用。Ames试验呈阴性，表明其无致突变作用。

虹鳟鱼LC₅₀为18.7毫克/升（96小时），野鸭和鹌鹑的LC₅₀分别为大于10000毫克/公斤饲料和2847毫克/公斤饲料。该物质无积累毒性。

化学性质

霜脲氰是一种白色结晶体，熔点为160～161℃，相对密度1.31（25℃），蒸气压约8×10^-5帕斯卡（25℃）。在25℃时的溶解度分别为：丙酮10.5%，二甲基甲酰胺18.5%，氯仿10.3%，甲醇4.1%，苯0.2%，己烷0.1%，水0.1%。正常贮存条件下稳定。

用途

霜脲氰是一种高效杀菌剂，具有内吸作用，与保护性杀菌剂混用能提高残留活性。它对霜霉目真菌（包括疫霉属、霜霉属和单轴霉属）有效。推荐剂量为0.9～1.2克/100平方米，用于防治马铃薯晚疫病和葡萄霜霉病。

此外，霜脲氰还适用于防治番茄、黄瓜等作物的霜霉病和晚疫病，以及黄瓜霜霉病。

生产方法

霜脲氰的合成过程包括以下步骤：

1. N-氰乙酰基-N-乙基脲 的制备：将98克N-乙基脲、94克氰乙酸和200克乙酸酐混合，升温至60℃并保持3小时。冷却后减压脱去乙酸，并用水处理结晶，最终得白色细针状结晶，熔点173℃。

2. 2-氰基-2-肟基乙酰胺 的制备：在氮气氛围下将甲醇、水与N-氰乙酰基-N-乙基脲混合，在40℃反应1小时后加入6摩尔/升盐酸，继续反应2小时。调节pH值至7～8。

3. 霜脲氰 的合成：缓加硫酸二甲酯，并用50% NaOH溶液维持pH值在7～8之间，在40℃下反应2小时后冷却至5℃，抽滤、水洗并干燥，再于无水乙醇中重结晶。

类别

• 农药
• 毒性分级：中毒
• 急性毒性：
  • 口服-大鼠 LD₅₀：1100毫克/公斤；
  • 腹腔注射-大鼠 LD₅₀：166毫克/公斤

安全与储存

• 可燃性危险特性：可燃；燃烧时产生有毒氮氧化物烟雾。
• 储运特性：库房通风、低温干燥；与氧化剂、碱类分开存放。
• 灭火剂：泡沫、二氧化碳、砂土、雾状水。

反应信息

• 作为产物：
  描述：

  1-氰乙酰基-3-乙基脲 在 碳酸氢钠 、 sodium nitrite 作用下， 以 乙腈 为溶剂， 生成 2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide
  参考文献：
  名称：

  Greci, Lucedio; Carloni, Patricia; Mandrioli, Odofredo, Journal of Chemical Research - Part S, 2003, # 10, p. 655 - 657

  摘要：

  DOI：

文献信息

• [EN] ACC INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE L'ACC ET UTILISATIONS ASSOCIÉES
  申请人：GILEAD APOLLO LLC

  公开号：WO2017075056A1

  公开（公告）日：2017-05-04

  The present invention provides compounds I and II useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, and methods of using the same.

  本发明提供了化合物I和II，这些化合物可用作乙酰辅酶A羧化酶（ACC）的抑制剂，以及它们的组合物和使用方法。
• [EN] BICYCLYL-SUBSTITUTED ISOTHIAZOLINE COMPOUNDS<br/>[FR] COMPOSÉS ISOTHIAZOLINE SUBSTITUÉS PAR UN BICYCLYLE
  申请人：BASF SE

  公开号：WO2014206910A1

  公开（公告）日：2014-12-31

  The present invention relates to bicyclyl-substituted isothiazoline compounds of formula (I) wherein the variables are as defined in the claims and description. The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to plant propagation material and to an agricultural and a veterinary composition comprising said compounds.

  本发明涉及公式（I）中变量如索权和说明中所定义的自行车基取代异噻唑啉化合物。这些化合物对抗或控制无脊椎动物害虫，特别是节肢动物害虫和线虫方面具有用途。该发明还涉及一种通过使用这些化合物来控制无脊椎动物害虫的方法，以及包含所述化合物的植物繁殖材料、农业和兽医组合物。
• [EN] AZOLINE COMPOUNDS<br/>[FR] COMPOSÉS AZOLINE
  申请人：BASF SE

  公开号：WO2015128358A1

  公开（公告）日：2015-09-03

  The present invention relates to azoline compounds of formula (I) wherein A, B1, B2, B3, G1, G2, X1, R1, R3a, R3b, Rg1 and Rg2 are as defined in the claims and the description. The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to plant propagation material and to an agricultural and a veterinary composition comprising said compounds.

  本发明涉及式（I）的噁唑啉化合物，其中A、B1、B2、B3、G1、G2、X1、R1、R3a、R3b、Rg1和Rg2如权利要求和描述中所定义。这些化合物对抗或控制无脊椎动物害虫，特别是节肢动物害虫和线虫方面具有用途。该发明还涉及一种利用这些化合物控制无脊椎动物害虫的方法，以及包括所述化合物的植物繁殖材料、农业和兽医组合物。
• [EN] SUBSTITUTED QUINAZOLINES AS FUNGICIDES<br/>[FR] QUINAZOLINES SUBSTITUÉES, UTILISÉES EN TANT QUE FONGICIDES
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：WO2010136475A1

  公开（公告）日：2010-12-02

  The present invention relates to a compound of formula (I) wherein wherein the substituents have the definitions as defined in claim 1or a salt or a N-oxide thereof, their use and methods for the control and/or prevention of microbial infection, particularly fungal infection, in plants and to processes for the preparation of these compounds.

  本发明涉及一种具有如下式（I）的化合物，其中取代基具有权利要求1中定义的定义，或其盐或N-氧化物，它们的用途以及用于控制和/或预防植物中微生物感染，特别是真菌感染的方法，以及制备这些化合物的方法。
• [EN] MICROBIOCIDAL OXADIAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS D'OXADIAZOLE MICROBIOCIDES
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：WO2017157962A1

  公开（公告）日：2017-09-21

  Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially fungicides.

  式(I)的化合物，其中取代基如权利要求1所定义，作为杀虫剂特别是杀菌剂有用。